Ladenburg Thalmann disclosed Brixmor Property (NYSE:BTX), hiking its price target to $6.00 earlier today
- Updated: September 23, 2016
Having a price of $3.59, Brixmor Property (NYSE:BTX) traded 6.16% higher on the day. With the last stock price up 31.53% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. BTX has recorded a 50-day average of $3.18 and a two hundred day average of $2.90. Trade Volume was up over the average, with 411,231 shares of BTX changing hands over the typical 282,164
Stating as potential upside of 0.67%, Ladenburg Thalmann raised the target price of Brixmor Property (NYSE:BTX) to $6.00
On Tuesday December 22, 2015, Oppenheimer released a statement about Brixmor Property (NYSE:BTX) upped the target price from $0.00 to $10.00 that suggested an upside of 1.41%.
Recent Performance Chart
Brixmor Property has 52 week low of $2.02 and a 52 week high of $4.51 and has a market capitalization of $0.
Brief Synopsis On Brixmor Property (NYSE:BTX)
BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company's pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient's own somatic or adult stem cells, at the desired location.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.